Detecting Lung Cancer Based on Exhaled Breath

Peking University

Status: Completed

Conditions: Lung Neoplasms; Lung Cancer; Carcinoma; NSCLC

Treatments: Diagnostic Test: Breath test

Study type: Observational

Funder types: Other

Identifiers

NCT04419207

2019PHB095-01

Details and patient eligibility

About

Early detection is critical to improve the overall survival of lung cancer. Endogenous volatile organic compounds (VOCs) can be derived from many different metabolic pathways. On the other hand, cancer cells have different metabolism patterns compared with normal cells. Thus, detecting VOCs in exhaled breath using highly sensitive mass spectrometry would be a promising approach for lung cancer detection.

Full description

Endogenous volatile organic compounds (VOCs) can be derived from many different metabolic pathways. VOCs can be transported to the alveoli through the blood circulation and expelled by exhalation. Changes in VOCs production, clearance, and alterations in lung air-blood exchange functions can lead to aberrant VOCs profiles in the exhaled breath. Testing exhaled breath has the advantages of being completely non-invasive and easy to collect, and has been considered as a perfect approach for disease diagnoses and therapeutic monitoring. Many clinical studies have found that VOCs in exhaled breath are closely related to disease status. Specific VOCs alterations have been identified in many tumors, especially lung cancer.

In this study, we use a highly sensitive mass spectrometry to detect exhaled VOCs of lung cancer patients and healthy people. A lung cancer diagnosis model based on mass spectrometry data and support vector machine will be initially established and validated.

Enrollment: 2,236 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria for inpatient :

• pulmonary nodules in competed tomography images
• plan to receive thoracic surgery

Inclusion Criteria for controls :

• have planned physical examination every year
• plan to receive low-dose computed tomography

Exclusion Criteria:

• history of malignant tumors.
• receive anti-tumor treatment such as radiotherapy, chemotherapy, targeted therapy before surgery
• with infections or liver disease

Trial design

2,236 participants in 2 patient groups

Patients with Surbery

Description:

Patients who with pulmonary nodules in computed tomography and planned to receive thoracic surgery will be included. And those who have other types of cancer, received anti-tumor treatment before surgery, liver disease, or infections will be excluded.

Treatment:

Diagnostic Test: Breath test

Healthy Controls

Description:

Adult participants (\>18 yr) who plan to receive annual physical examination and low-dose computed tomography will be included. And those who have history cancers, received anti-tumor treatment before surgery, liver disease, or infections will be excluded.

Treatment:

Diagnostic Test: Breath test